Study of Tislelizumab and Chemoradiation for Low Rectal Cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of the immunotherapy drug tislelizumab with standard chemotherapy and radiation before surgery to see if it can help patients with low rectal cancer avoid surgery or keep their organs. It is for people whose tumors are close to the anus and have not spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with a type of rectal cancer called adenocarcinoma that is not aggressive or rare (confirmed by lab tests).
- The bottom edge of your tumor is within 2 inches (5 cm) of the anal opening.
- Your cancer is at an early or moderately advanced stage (cT1-3N0-1M0) and can be removed by surgery.
- You have not had any prior treatment for rectal cancer, and your overall health is good (ECOG score 0 or 1).
- You are willing to use highly effective birth control during the study and for 4 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests if adding an immunotherapy drug (tislelizumab) to standard chemoradiation and chemotherapy helps patients with ultra-low rectal cancer. It is for patients whose cancer has not spread and can be removed with surgery.
This trial tests a combination of an immunotherapy drug (tislelizumab) plus chemotherapy before surgery for people with a specific type of rectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor more effectively than standard treatment.
This trial tests a new combination of treatments (radiation, immunotherapy, and two chemotherapy drugs) given before surgery for people with a specific type of locally advanced rectal cancer that is close to the anus. The goal is to see if this approach is safe and effective.
This trial tests whether combining chemotherapy, immunotherapy (PD-1 inhibitor), and a precise type of radiation can help shrink locally advanced rectal cancer before surgery. It aims to improve treatment success and reduce side effects.
This trial is testing a combination of immunotherapy (PD-1 antibody) with a targeted biologic (IL-2) and chemotherapy (CapeOX) to shrink advanced rectal cancers located very low in the rectum. The goal is to avoid surgery and preserve the rectum and its function.
Hear when a new Rectal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.